Clinical Trials Logo

Advanced Tumors clinical trials

View clinical trials related to Advanced Tumors.

Filter by:

NCT ID: NCT04198818 Terminated - Melanoma Clinical Trials

A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of HH2710 in Patient With Advanced Tumors

Start date: January 7, 2020
Phase: Phase 1/Phase 2
Study type: Interventional

This is a First-in-Human, Open Label, Phase I/II Study to Evaluate the Safety, Tolerability and Pharmacokinetics of HH2710 in Patients with Advanced Tumors, composed of a Phase I dose escalation and dose expansion stage and a Phase II dose extension stage.

NCT ID: NCT04151810 Not yet recruiting - Advanced Tumors Clinical Trials

Phase I Clinical Trial of CDP1 in Patients With Advanced Solid Tumors

Start date: December 30, 2019
Phase: Phase 1
Study type: Interventional

The main purpose of this study was to evaluate the safety and tolerability of CDP1 in patients with advanced solid tumor, to explore dose limited toxicity (DLT), and to determine the recommended dose (RP2D) for phase II clinical trials.

NCT ID: NCT03908814 Recruiting - Advanced Tumors Clinical Trials

Phase I Clinical Trial of Human Anti-PD-L1 Antibody Injection (LDP) in Patients With Advanced Malignant Tumors

Start date: April 27, 2019
Phase: Phase 1
Study type: Interventional

This is a phase I, open-label, multiple-dose, dose-escalation study to evaluate the safety, tolerability, pharmacokinetics and anti-tumor activity of LDP in subjects with advanced malignant tumors.

NCT ID: NCT03781362 Completed - Advanced Tumors Clinical Trials

Study of CPI-100 in Patients With Advanced Tumors

Start date: December 21, 2018
Phase: Phase 1
Study type: Interventional

This is a prospective, open-label, 2-arm, non-randomized study of CPI-100 in patients with advanced tumors. CPI-100 is administered via intravenous infusion in a 3 + 3 study design to identify the maximum tolerated dose (MTD).

NCT ID: NCT03444714 Recruiting - Advanced Tumors Clinical Trials

Phase I Study of RiMO-301 With Radiation in Advanced Tumors

Start date: April 10, 2018
Phase: Phase 1
Study type: Interventional

This is a prospective, open-label, single arm, non-randomized study of RiMO-301 with radiation in patients with advanced tumors. A single escalation dose of RiMO-301 is intratumorally injected in a 3 + 3 study design to identify the recommended dose and dosing volumes. Condition or Disease: Patient with advanced tumor which is clinically accessible for intratumoral injection Intervention/Treatment: Drug - RiMO-301 Radiation - Radiotherapy Phase: Phase 1

NCT ID: NCT02419417 Completed - Advanced Tumors Clinical Trials

Study of BMS-986158 in Subjects With Select Advanced Cancers

BET
Start date: June 19, 2015
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to determine the safety, tolerability, pharmacokinetics, and pharmacodynamics of BMS-986158 in subjects with select advanced cancers